About TGN
“Genotype” is the genetic constitution of an organism. The genotype determines the hereditary potentials (and limitations) of an individual from embryonic formation through adulthood.
The Genotype Network selects lawyers with - figuratively speaking - the genotype with the most potential to optimize the success of transactions in the pharma & biotech space.
Life sciences pertains to: pharma, biotech and medical devices, such as companion diagnostics.
Deals in this sector are becoming increasingly complex and larger in size. The deal size of two large deals in biopharma, announced in the first half of year was $12,6 and $3,33 billion. The largest deal in pharma ever was the merger of Warner-Lambert with Pfizer in 2000, for which Pfizer paid $90 billion. More recent deals were the acquisition of Allergan by AbbVie and Celgene by Bristol-Myers-Squibb for for $63 and $74 billion, respectively, both in 2019. This type of deals takes place in a highly regulated environment and therefore always require outstanding regulatory expertise.
TGN connects corporate and regulatory lawyers who are active in pharma & biotech on a global scale to ensure buy-side performs the most optimal due diligence possible, including more innovative analyses of the target. Obviously, companies require help understanding the value of the assets they are planning to purchase or to invest in. Furthermore, regulatory issues more and more go to valuation. If there is a significant problem regulatory-wise, this could have impact on the transaction price.
Moreover, if the deal can be structured with the regulatory components in mind from the start, the chances of limitations later in the process are much lower. Furthermore, this provides the opportunity to arrange issues with the competent authorities, if needed. If regulatory issues come to light in a late stage, it may affect the entire life-span of the deal.